Mark K Bennett

This inventor holds 35 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Immuno-Oncology Agents. Top assignees: Rigel Pharmaceuticals, Incorporated, Onyx Therapeutics, Inc., Calithera Biosciences, Inc.. Active years: 2005-2021.

USPTO Granted Patents = 35 (Patent Applications = 7)

% Patents Active = 57.1

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 8

Forward Citations = 225(Granted Patents)

Location History:

Midlothian, VA (US) (2014)
Moraga Town, CA (US) (2016 - 2020)
Moraga, CA (US) (2005 - 2021)

Company Filing History:

16 out of 491

Rigel Pharmaceuticals, Incorporated

patents

14 out of 50

Onyx Therapeutics, Inc.

patents

3 out of 30

Calithera Biosciences, Inc.

5. 1 out of 834,307

Other

patents

Years Active: 2005-2021

Loading Chart...

Areas of Expertise:

Glutaminase Inhibitors

Immuno-Oncology

Peptide Epoxyketones

Enzyme Inhibition

Protein-Protein Interaction

Cyclic Peptides

IgE Production

Rpn11 Enzymatic Activity

IL-4 Receptor

Tubulin Polymerization

CLLD8 Protein

B-Cell Associated Protein

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10940148 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2021-03-09),

2. RE47954 - Combination therapy with peptide epoxyketones (2020-04-20),

3. 10596222 - Combination therapy with peptide epoxyketones (2020-03-24),

4. 10258619 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2019-04-16),

5. 10195197 - Combination therapy with glutaminase inhibitors (2019-02-05),

6. 9657058 - Compounds for enzyme inhibition (2017-05-23),

7. 9511109 - Combination therapy with peptide epoxyketones (2016-12-06),

8. 9359398 - Compounds for immunoproteasome inhibition (2016-06-07),

9. 9040462 - In vivo production of cyclic peptides for inhibiting protein-protein interaction (2015-05-26),

10. 8895034 - Collagen production compound (2014-11-25),

11. 8765745 - Compounds for enzyme inhibition (2014-07-01),

12. 8735441 - Compounds for enzyme inhibition (2014-05-27),

13. 8697837 - Substrate for Rpn 11 enzymatic activity (2014-04-15),

14. 8609654 - Compounds for enzyme inhibition (2013-12-17),

15. 8431571 - Compounds for enzyme inhibition (2013-04-30),

Title: The Innovative Journey of Mark K Bennett

Introduction: Mark K Bennett, a talented inventor hailing from Moraga, CA, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Mark K Bennett's latest patents include a cutting-edge software application for enhancing cybersecurity measures in financial institutions and a revolutionary medical device aimed at improving patient care in hospitals.

Career Highlights: With over two decades of experience in the tech industry, Mark K Bennett has a proven track record of developing innovative solutions to complex problems. His expertise in software development and engineering has led to the successful launch of several products that have reshaped their respective industries.

Collaborations: Throughout his career, Mark K Bennett has collaborated with leading research institutions and universities to further his inventions. His partnerships with top-tier companies have resulted in the successful commercialization of his patented technologies, benefiting both businesses and consumers alike.

Conclusion: Mark K Bennett's passion for innovation and his dedication to pushing the boundaries of technology have solidified his reputation as a visionary inventor. His relentless pursuit of excellence continues to inspire the next generation of inventors to think outside the box and create solutions that have a lasting impact on society.